Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Orelabrutinib hos patienter med sekundær progressiv multipel sklerose

6. november 2026 opdateret af: Zenas BioPharma (USA), LLC

En fase 3, randomiseret, dobbeltblind effektivitets- og sikkerhedsundersøgelse, der sammenligner Orelabrutinib med placebo hos patienter med ikke-aktiv sekundær progressiv multipel sklerose

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

The study consists of the following periods:

  • Screening Period: Up to 4 weeks.
  • Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
  • Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
  • Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
  • Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).

All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

990

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New South Wales
      • Kogarah, New South Wales, Australien, 2217
        • Rekruttering
        • Southern Neurology Suite 2
      • Sovet, Belgien, 1408
        • Rekruttering
        • DCC Neoclinic - Sofia
    • Limburg
      • Overpelt, Limburg, Belgien, 3900
        • Rekruttering
        • MS-Netwerk Limburg - Revalidatie
      • Pleven, Bulgarien, 5800
        • Rekruttering
        • Avis Medica Hospital Pleven
    • Plovdiv
      • Plovdiv, Plovdiv, Bulgarien, 4000
        • Rekruttering
        • Medical Center Nevrocentrum
    • Sofia
      • Sofia, Sofia, Bulgarien, 1680
        • Rekruttering
        • Diagnostic and Consultative Center Convex
      • Sofia, Sofia, Bulgarien, 1510
        • Rekruttering
        • Medical Center Hera EOOD
    • Tarnovo
      • Veliko Tarnovo, Tarnovo, Bulgarien, 5000
        • Rekruttering
        • Medical Center Medica Plus OOD
    • Harju
      • Tallinn, Harju, Estland, 10617
        • Rekruttering
        • Astra clinic (Clinic4U)
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85032
        • Rekruttering
        • Arizona Neuroscience Research, LLC
      • Scottsdale, Arizona, Forenede Stater, 85253
        • Rekruttering
        • Perseverance Research Center, LLC (PRC)
    • California
      • Fullerton, California, Forenede Stater, 92835
        • Rekruttering
        • Fullerton Neurology and Headache Center
      • Torrance, California, Forenede Stater, 90502-2006
        • Rekruttering
        • Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
      • West Hollywood, California, Forenede Stater, 90048
        • Rekruttering
        • Regina Berkovich MD, PhD Inc
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33487
        • Rekruttering
        • SFM Clinical Research, LLC
      • Bradenton, Florida, Forenede Stater, 34209
        • Rekruttering
        • Nova Clinical Research, LLC
      • Clearwater, Florida, Forenede Stater, 33761
        • Rekruttering
        • MS and Neuromuscular Center of Excellence
      • Maitland, Florida, Forenede Stater, 32751
        • Rekruttering
        • Neurology Associates
      • Naples, Florida, Forenede Stater, 34105
        • Rekruttering
        • Aqualane Clinical Research
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • University of South Florida Department of Neurology - MS Division
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46256
        • Rekruttering
        • Josephson Wallack Munshower Neurology, Pc Suite 225
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Medical Center
      • Roeland Park, Kansas, Forenede Stater, 66205
        • Rekruttering
        • KC Research Center, PA Neurology Research Dept
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02131
        • Trukket tilbage
        • Boston Clinical Trials
      • Worcester, Massachusetts, Forenede Stater, 01655
        • Rekruttering
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Rochester Hills, Michigan, Forenede Stater, 48307
        • Rekruttering
        • Profound Research LLC at Oakland Neurology Center
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87131
        • Rekruttering
        • University Of New Mexico School Of Medicine
    • New York
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Mount Sinai Medical Center
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43235
        • Rekruttering
        • The Boster Center for Multiple Sclerosis
      • Columbus, Ohio, Forenede Stater, 43221
        • Rekruttering
        • The Ohio State University Wexner Medical Center (OSUWMC)
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • OMRF Multiple Sclerosis Center of Excellence
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • Premier Neurology
    • Tennessee
      • Cordova, Tennessee, Forenede Stater, 38018
        • Rekruttering
        • Neurology Clinic, P.C.
    • Texas
      • San Antonio, Texas, Forenede Stater, 78258
        • Rekruttering
        • Lone Star Neurology
      • Sherman, Texas, Forenede Stater, 75092
        • Rekruttering
        • Texas Institute for Neurological Disorders - Sherman
    • Brest
      • Pordic, Brest, Frankrig, 29609
        • Rekruttering
        • CHU Brest Hospital Cavale
    • Gard
      • Nîmes, Gard, Frankrig, 30029
        • Rekruttering
        • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
    • Yveline
      • Poissy, Yveline, Frankrig, 78300
        • Rekruttering
        • Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
      • Tbilisi, Georgien, 0114
        • Rekruttering
        • LTD Pineo Medical Ecosystem
      • Tbilisi, Georgien, 0186
        • Rekruttering
        • Raymann, LLC
      • Tbilisi, Georgien, 0159
        • Rekruttering
        • NNLE Jo Ann University Hospital
      • Tbilisi, Georgien, 0186
        • Rekruttering
        • Caucasus Medical Center Ltd
    • K'alak'i T'bilisi
      • Tbilisi, K'alak'i T'bilisi, Georgien, 0114
        • Rekruttering
        • JSC Curatio
    • Saburtalo
      • Tbilisi, Saburtalo, Georgien, 0160
        • Rekruttering
        • MD Georgia Staff Physician MediClub Georgia
    • Athens
      • Cholargós, Athens, Grækenland, 15562
        • Rekruttering
        • Metropolitan General Hospital
    • Attica
      • Athens, Attica, Grækenland, 11526
        • Rekruttering
        • Errikos Dunant Hospital
    • Chieti
      • Chieti, Chieti, Italien, 66100
        • Rekruttering
        • University G. D'Annunzio of Chieti-Pescara
    • Isernia/Molise
      • Pozzilli, Isernia/Molise, Italien, 86077
        • Rekruttering
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
      • Zagreb, Kroatien, 10 000
        • Rekruttering
        • Klinicki Bolnicki Centar Zagreb-Rebro
    • Kauno
      • Kaunas, Kauno, Litauen, 50161
        • Rekruttering
        • Hospital of Lithuanian University of Health Sciences
      • Lublin, Polen, 20-064
        • Rekruttering
        • Galen Clinic
      • Plewiska, Polen, 62-064
        • Rekruttering
        • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
      • Poznan, Polen, 15-540
        • Rekruttering
        • Prywatna Lecznica Certus Sp. z o.o.
      • Szczecin, Polen, 70-111
        • Rekruttering
        • EUROMEDIS Osrodek Badan Klinicznych
      • Żory, Polen, 44-240
        • Rekruttering
        • Centrum Medyczne ProNeuro Żory
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
        • Rekruttering
        • Centrum Medyczne INTERCOR Sp. z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-601
        • Rekruttering
        • Malva Trials
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekruttering
        • Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekruttering
        • NZOZ Neuromed M. i M. Nastaj Sp.P
    • Lubusz Voivodeship
      • Nowa Sól, Lubusz Voivodeship, Polen, 67-100
        • Rekruttering
        • Twoja Przychodnia Centrum Medyczne Nowa Sól
    • Mazovian
      • Warsaw, Mazovian, Polen, 02-172
        • Rekruttering
        • MTZ Clinical Researcz Powered by pratia
    • Rzeszów
      • Rzeszów, Rzeszów, Polen, 35-323
        • Rekruttering
        • Nmedis sp. z o.o.
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-081
        • Rekruttering
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, Polen, 40-571
        • Rekruttering
        • MA-LEK Clinical Sp. z o.o.
      • Katowice, Silesian Voivodeship, Polen, 40-584
        • Rekruttering
        • NZOZ Novo Med
    • Upper Silesia
      • Katowice, Upper Silesia, Polen, 40-686
        • Rekruttering
        • Neuro Medic Clinic
    • Wielkopolska
      • Poznan, Wielkopolska, Polen, 61-853
        • Rekruttering
        • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
      • Poznan, Wielkopolska, Polen, 60-324
        • Rekruttering
        • Twoja Przychodnia PCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 91-743
        • Rekruttering
        • PRO SALUS Sp. z o.o. sp.k.
      • Lodz, Łódź Voivodeship, Polen, 90-324
        • Rekruttering
        • Centrum Neurologii Krzysztof Selmaj
      • Guaynabo, Puerto Rico, 00969
        • Rekruttering
        • Caribbean Center for Clinical Research
    • Constanța County
      • Constanța, Constanța County, Rumænien, 900123
        • Rekruttering
        • Spital Clinic CF Constanta
    • Suceava
      • Radauti, Suceava, Rumænien, 725400
        • Rekruttering
        • Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
      • Kragujevac, Serbien, 34000
        • Rekruttering
        • University Clinical Centre of Kragujevac
      • Niš, Serbien, 18000
        • Rekruttering
        • Clinic of Neurology - Clinical Center Nis
    • Belgrade
      • Belgrade, Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Centre of Serbia
    • A Coruña
      • A Coruña, A Coruña, Spanien, 15006
        • Rekruttering
        • Complejo Hospitalario Universitario A Coruña
    • Galicia
      • Vigo, Galicia, Spanien, 36312
        • Rekruttering
        • Hospital Alvaro Cunqueiro
    • Madrid
      • Madrid, Madrid, Spanien, 28007
        • Rekruttering
        • Hospital Gregorio Marañon
      • Majadahonda, Madrid, Spanien, 28222
        • Rekruttering
        • Hospital Universitario Puerta de Hierro de Majadahonda
    • Málaga
      • Málaga, Málaga, Spanien, 29016
        • Rekruttering
        • Vithas Hospital Parque San Antonio
    • Seville
      • Castilleja de la Cuesta, Seville, Spanien, 41950
        • Rekruttering
        • Hospital Vithas Nisa Sevilla
      • Choceň, Tjekkiet, 56501
        • Rekruttering
        • NEUROHK, s.r.o.
      • Jihlava, Tjekkiet, 58601
        • Rekruttering
        • Regional Hospital Jihlava
    • Hesse
      • Bad Homburg, Hesse, Tyskland, 61348
        • Rekruttering
        • Zentrum fur klinische Forschung Dr.Scholl GmbH
      • Ivano-Frankivsk, Ukraine, 76943
        • Rekruttering
        • Neuro Global
      • Lviv, Ukraine, 79010
        • Rekruttering
        • Lviv National Medical University named after Danylo Galytskiy
      • Vinnytsia, Ukraine, 21009
        • Rekruttering
        • Medical Clinical Investigational Center of Medical Center LLC Health Clinic
    • Chernivtsi Oblast
      • Chernivtsi, Chernivtsi Oblast, Ukraine, 58023
        • Rekruttering
        • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
    • Ivano-Frankivs'k Oblast
      • Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraine, 76018
        • Rekruttering
        • CNE City Clinical Hospital #1 of Ivano-Frankivsk council
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79000
        • Rekruttering
        • Limited Liability Company Medical Center Neuroclinic
      • Lviv, Lviv Oblast, Ukraine, 79029
        • Rekruttering
        • Limited Liability Company "Neurofocus"
      • Budapest, Ungarn, 1145
        • Rekruttering
        • National Institute of Clinical Neurosciences
      • Tatabánya, Ungarn, 2800
        • Rekruttering
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Komarom-Esztergom Vamegye
      • Esztergom, Komarom-Esztergom Vamegye, Ungarn, 2500
        • Rekruttering
        • Valeomed Kft.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 60 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
  3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
  4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
  5. Absence of clinical relapses for at least 24 months.

Exclusion Criteria:

  1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
  2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
  3. History or current diagnosis of other neurological disorders that may mimic MS
  4. History or current diagnosis of progressive multifocal leukoencephalopathy
  5. Active, clinically significant viral, bacterial, or fungal infection
  6. History of any other significant active medical condition
  7. History of suicidal behavior within 6 months prior to Screening
  8. Any prior history of malignancy
  9. Patients on anticoagulation, or antiplatelet therapy
  10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
  11. Clinically significant laboratory abnormalities at Screening.
  12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
  13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Orelabrutinib Group

Orelabrutinib PO daily

Orelabrutinib orally

Placebo komparator: Placebo Group

Placebo PO daily

Placebo orally

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Tidsramme: Up to approximately 120 weeks

Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0

Up to approximately 120 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
12 Week CDP
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on EDSS, confirmed over at least 12 weeks

Up to approximately 120 weeks
T2 lesions on MRI
Tidsramme: Up to approximately 120 weeks

The total number of new or enlarging T2 lesions on MRI scans of the brain

Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDP-T25FWT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI
Tidsramme: Up to approximately 120 weeks

Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-9HPT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-T25FWT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
Symbol Digit Modalities Test
Tidsramme: Up to approximately 120 weeks

The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit

Up to approximately 120 weeks
Annualized relapse rate
Tidsramme: Up to approximately 120 weeks

Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses

Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Tidsramme: Up to approximately 120 weeks

Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);

Up to approximately 120 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. marts 2026

Primær færdiggørelse (Anslået)

1. juni 2030

Studieafslutning (Anslået)

1. juli 2030

Datoer for studieregistrering

Først indsendt

18. december 2025

Først indsendt, der opfyldte QC-kriterier

19. december 2025

Først opslået (Faktiske)

23. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ZB020-03-002

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .